Plasmodium falciparum erythrocyte binding protein baebl for use as a vaccine
OwnerGhislaine Mayer, Louis Millerinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to Plasmodium falciparum Erythrocyte Binding Protein BAEBL for use as a vaccine.
Claims23
A vaccine composition comprising a polypeptide and a pharmaceutically acceptable vehicle, wherein the polypeptide comprises an amino acid sequence that encodes a BAEBL polypeptide or portion thereof.
A vaccine composition comprising a polynucleotide and a pharmaceutically acceptable vehicle, wherein the polynucleotide comprises a nucleic acid sequence that encodes a BAEBL polypeptide or portion thereof.
A method of vaccinating a human against a malaria Plasmodium parasite comprising the step of administering antibodies specific for the binding site of a BAEBL ligand in an amount sufficient to inhibit the ligand from binding red blood cells in the human.
Dependencies are inferred from the claim text.